UNSPSC 51284805: Ichthammol/lanolin/petrolatum

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE101. This VA Drug Class (DE101) classifies this compound as belonging to the group ANTIBACTERIAL, TOPICAL.

UNSPSC 51284805 Ichthammol/lanolin/petrolatum is a Commodity-tier code that shows minimal recent alignment with state and local procurement activity; the code's nominal scope—a niche pharmaceutical base compound used in topical preparations—does not match the work actually being solicited under this code designation. The recent opportunities tagged to this code instead cover naloxone procurement, direct-to-manufacturer prescription initiatives, emergency medical supplies, and generic multi-source pharmaceutical programs. None of these solicitations involve ichthammol, lanolin, or petrolatum formulations. The issuing bodies include Seminole County, Florida (health initiatives); Texas Health and Human Services Commission (pharmacy benefit administration); City of Tampa (fire rescue); and the Minnesota Multistate Cooperative Purchasing Alliance (state and local pharmaceutical distribution). This divergence between the code's abstract name and actual procurement activity suggests either misclassification in the posting metadata or that the code is used as a catch-all for pharmaceutical and medical-supply categories outside their more specific taxonomy slots.

Activity is geographically scattered across Florida, Texas, Minnesota (serving multiple states including Oregon), and other participating jurisdictions in cooperative purchasing arrangements. Representative recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units annually, quarterly deliveries, response deadline July 26, 2023); the City of Tampa's IFB for medical and first aid supplies targeting the Fire Department Rescue Division (169 line items, $700,000 estimated value, SLBE-sheltered with a 5 percent discount, response deadline March 13, 2026); MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (responses due March 26, 2026, contract effective July 1, 2026, serving multiple state and local facilities across participating jurisdictions); and Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (responses due April 3, 2026, exploratory stage for future formalized procurement). Vendors pursuing this code should expect to navigate cooperative purchasing vehicles, multi-state or multi-jurisdiction agreements, and the distinction between direct-to-government contracting and wholesaler-intermediated supply chains, though the nominal code scope itself remains disconnected from recent procurement patterns.